Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313373378> ?p ?o ?g. }
Showing items 1 to 80 of
80
with 100 items per page.
- W4313373378 endingPage "237.8" @default.
- W4313373378 startingPage "237.8" @default.
- W4313373378 abstract "Abstract Spondyloarthritis (SpA) is the most common extra-intestinal manifestation of inflammatory bowel disease (IBD). Sulfasalazine (SAS) is one of the earliest medications used in IBD and its efficacy in spondyloarthritis is thought to depend on its antibacterial properties. Therefore, our study aims to diagnostically evaluate the role for the fecal microbiome in clinical response to SAS and identify microbial and immunologic therapeutic targets associated with clinical response. We have longitudinally followed IBD-SpA patients subjected to SAS therapy. Clinical data, including validated IBD and joint disease activity scores, and fecal samples from 19 patients were collected at baseline and at week 2 and 12 after SAS initiation. Metagenomic sequencing was used to define the effect of SAS on the IBD-SpA fecal microbiome and to evaluate its relationship with joint symptoms improvement. Gnotobiotic mouse models were used to test the sufficiency of the SAS effect observed in patients. Fecal microbiome of SAS-responders was distinct from that of non-responders and 6 pre-treatment microbial markers (including Faecalibacterium prausnitzii) predicted SAS-response (AUC: 0.9). SPF mice and germ-free mice colonized with patient microbiota revealed that SAS selectively reduced mucosal-associated bacteria. Gnotobiotic mouse models revealed a critical role for A. muciniphila in modulating mucosal inflammation. Our study reveals the ability of SAS to selectively target mucosal-associated bacteria and modulate the inflammatory impact of IBD-SpA associated pathobionts. This study highlights the potential use of microbial-based diagnostic tools to improve drug efficacy and therapeutic strategies for IBD-SpA." @default.
- W4313373378 created "2023-01-06" @default.
- W4313373378 creator A5006010540 @default.
- W4313373378 creator A5008502344 @default.
- W4313373378 creator A5031846935 @default.
- W4313373378 creator A5039945343 @default.
- W4313373378 creator A5055566451 @default.
- W4313373378 creator A5063280893 @default.
- W4313373378 creator A5072439892 @default.
- W4313373378 creator A5072749993 @default.
- W4313373378 creator A5075962876 @default.
- W4313373378 creator A5077920062 @default.
- W4313373378 creator A5086709630 @default.
- W4313373378 date "2020-05-01" @default.
- W4313373378 modified "2023-09-28" @default.
- W4313373378 title "Defining the role for the gut microbiome in the clinical efficacy of sulfasalazine therapy for IBD associated spondyloarthritis" @default.
- W4313373378 doi "https://doi.org/10.4049/jimmunol.204.supp.237.8" @default.
- W4313373378 hasPublicationYear "2020" @default.
- W4313373378 type Work @default.
- W4313373378 citedByCount "0" @default.
- W4313373378 crossrefType "journal-article" @default.
- W4313373378 hasAuthorship W4313373378A5006010540 @default.
- W4313373378 hasAuthorship W4313373378A5008502344 @default.
- W4313373378 hasAuthorship W4313373378A5031846935 @default.
- W4313373378 hasAuthorship W4313373378A5039945343 @default.
- W4313373378 hasAuthorship W4313373378A5055566451 @default.
- W4313373378 hasAuthorship W4313373378A5063280893 @default.
- W4313373378 hasAuthorship W4313373378A5072439892 @default.
- W4313373378 hasAuthorship W4313373378A5072749993 @default.
- W4313373378 hasAuthorship W4313373378A5075962876 @default.
- W4313373378 hasAuthorship W4313373378A5077920062 @default.
- W4313373378 hasAuthorship W4313373378A5086709630 @default.
- W4313373378 hasConcept C126322002 @default.
- W4313373378 hasConcept C143121216 @default.
- W4313373378 hasConcept C203014093 @default.
- W4313373378 hasConcept C2778260677 @default.
- W4313373378 hasConcept C2779134260 @default.
- W4313373378 hasConcept C2779383735 @default.
- W4313373378 hasConcept C2780479503 @default.
- W4313373378 hasConcept C2780675110 @default.
- W4313373378 hasConcept C539455810 @default.
- W4313373378 hasConcept C60644358 @default.
- W4313373378 hasConcept C61716771 @default.
- W4313373378 hasConcept C71924100 @default.
- W4313373378 hasConcept C86803240 @default.
- W4313373378 hasConcept C89423630 @default.
- W4313373378 hasConceptScore W4313373378C126322002 @default.
- W4313373378 hasConceptScore W4313373378C143121216 @default.
- W4313373378 hasConceptScore W4313373378C203014093 @default.
- W4313373378 hasConceptScore W4313373378C2778260677 @default.
- W4313373378 hasConceptScore W4313373378C2779134260 @default.
- W4313373378 hasConceptScore W4313373378C2779383735 @default.
- W4313373378 hasConceptScore W4313373378C2780479503 @default.
- W4313373378 hasConceptScore W4313373378C2780675110 @default.
- W4313373378 hasConceptScore W4313373378C539455810 @default.
- W4313373378 hasConceptScore W4313373378C60644358 @default.
- W4313373378 hasConceptScore W4313373378C61716771 @default.
- W4313373378 hasConceptScore W4313373378C71924100 @default.
- W4313373378 hasConceptScore W4313373378C86803240 @default.
- W4313373378 hasConceptScore W4313373378C89423630 @default.
- W4313373378 hasIssue "1_Supplement" @default.
- W4313373378 hasLocation W43133733781 @default.
- W4313373378 hasOpenAccess W4313373378 @default.
- W4313373378 hasPrimaryLocation W43133733781 @default.
- W4313373378 hasRelatedWork W1919509010 @default.
- W4313373378 hasRelatedWork W2024552926 @default.
- W4313373378 hasRelatedWork W2049558498 @default.
- W4313373378 hasRelatedWork W2119412188 @default.
- W4313373378 hasRelatedWork W2135233223 @default.
- W4313373378 hasRelatedWork W2408939568 @default.
- W4313373378 hasRelatedWork W2418837291 @default.
- W4313373378 hasRelatedWork W2765379856 @default.
- W4313373378 hasRelatedWork W4378388631 @default.
- W4313373378 hasRelatedWork W2186812870 @default.
- W4313373378 hasVolume "204" @default.
- W4313373378 isParatext "false" @default.
- W4313373378 isRetracted "false" @default.
- W4313373378 workType "article" @default.